Results 191 to 200 of about 28,157 (212)
The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old
Charlie McLeod, Michael Dymock, Katie L. Flanagan, Magdalena Plebanski, Helen Marshall, Marie J. Estcourt, Ushma Wadia, Christian Tjiam, Christopher C. Blyth, Kanta Subbarao, Francesca L. Mordant, Suellen Nicholson, Natalie Cain, Rianne Brizuela, Saul N. Faust, Ruth B. Thornton, Anne McKenzie, Julie Marsh, Tom Snelling, Peter Richmond +19 moreopenalex +1 more sourceA triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial. [PDF]
TrialsMusa AZ, Salako AO, Ayorinde JB, Ekama S, Odubela OO, Ige F, Idigbe IE, Ajibaye O, Odubela OR, Egharevba H, Ekpenyong M, Adeneye K, Folahanmi AT, Olojo II, Fowora MA, Okwuraiwe A, Elemuwa U, Ezenyi I, Fraden B, Oba A, Idris GA, Jimoh Y, Akande IR, Ogunwale J, Nwaiwu SO, Omale OL, Oyewunmi OO, Ezeanowi R, Agbabiaka A, Eyinade O, Osho A, Garba A, Yahya B, Musa BM, Ezejiofor O, Ejiro B, Iwalokun BA, Adigwe OP, Adeyeye MC, Faisal S, Ezechi OC, Salako BL. +41 moreeuropepmc +1 more sourceImpaired SARS-CoV-2 vaccine responsiveness is not associated with subclinical atherosclerosis or cardiovascular disease. [PDF]
Eur Heart J OpenAndersson SHA, Chalou A, Mulholland M, Katra P, Ljungcrantz I, Andersson L, Engström G, Nilsson J, Schiopu A, Björkbacka H, Engelbertsen D. +10 moreeuropepmc +1 more sourceNeutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses. [PDF]
Front ImmunolCaetano BLL, Pinto PBA, Pacheco AR, Lage AR, Pereira ASG, Nascimento AVP, Machado TR, Paulino A, Medeiros TL, Fernandes-Siqueira LO, Da Poian AT, Horbach IS, Azevedo AS, Costa SM, Alves AMB. +14 moreeuropepmc +1 more sourceReplacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation. [PDF]
Sci AdvZhao Y, Tian Z, Wang J, Cui M, Cao Z, Liu P, Li R, Cai S, Hu Y, Ma Y, Wagner E, Laflin A, Gu W, Cui Y, Tang C, Fountain H, Wang R, Jiang S. +17 moreeuropepmc +1 more sourceImpact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study. [PDF]
Vaccines (Basel)Sartori NS, Machado KLLL, Miyamoto ST, Pretti FZ, Gouveia MDPG, Oliveira YGP, da Silva VG, Faé F, Burian APN, Tapia KRL, Moulin ACS, Grillo LL, Athayde PDS, Corona HDS, Ramos SS, Peixoto FMMMC, Ribeiro PDC, Magalhães VO, de Aguiar MF, Biegelmeyer E, Kayser C, De Souza AWS, Castro CHM, Bühring J, Ribeiro SLE, Oliveira Dos Santos SH, Martins CP, da Silva Rodrigues JW, Sousa Dias MM, Dutra BG, Telles CMPF, Basualto Dias SE, de Rezende RPV, Baptista KL, Gaudio RC, de Melo AKG, da Silva VB, Cruz VA, Rêgo J, Vieira RMRA, Vieira ASR, Kakehasi AM, Tavares ACFMG, Pereira AJA, da Costa PVT, Azevedo VF, Pamplona Bueno de Andrade N, Tres GL, Assis Martins-Filho O, Peruhype-Magalhães V, Valim V, Ferreira GA, Teixeira-Carvalho A, Dos Reis-Neto ET, Sato EI, Pinheiro MM, de Souza VA, Xavier RM, Pileggi GS, Monticielo OA, SAFER-Study Group Task Force. +60 moreeuropepmc +1 more sourceReduced spike specific T-cell responses in COVID-19 vaccinated subjects undergoing SARS-CoV-2 breakthrough infection. [PDF]
Front ImmunolVarchetta S, Golfetto FS, Bono P, Callegaro A, Fabbris T, Favalli A, Crosti M, De Feo TM, Iannotti N, Bozzi G, Castelli V, Mariani B, Muscatello A, Abrignani S, Grifantini R, Bandera A, Lombardi A. +16 moreeuropepmc +1 more sourceMAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines. [PDF]
Sci ImmunolAmini A, Garner LC, Shaw RH, Kelly NW, Adele S, Skelly DT, Dejnirattisai W, Greenland M, Liu X, Heslington A, Hackstein CP, Murray SM, Vano CR, Stafford L, Johnson S, Sayaf K, Pudjohartono MF, Clutterbuck EA, PITCH Consortium‡, Com-COV Study Group‡, Bibi S, Conlon CP, James T, Jeffery K, Kronsteiner B, Mentzer AJ, O'Shea D, Ramasamy MN, Screaton GR, Snape MD, Hogan AE, Barnes E, Lambe T, Dunachie SJ, Provine NM, Klenerman P, PITCH Consortium, Com-COV Study Group. +37 moreeuropepmc +1 more source
